PL445128A1 - Peptydowe pochodne 1-(2-hydroksyetylo)-1H-pirolo-2,5-dionu, zastosowanie medyczne tych związków oraz sposób ich otrzymywania - Google Patents

Peptydowe pochodne 1-(2-hydroksyetylo)-1H-pirolo-2,5-dionu, zastosowanie medyczne tych związków oraz sposób ich otrzymywania

Info

Publication number
PL445128A1
PL445128A1 PL445128A PL44512823A PL445128A1 PL 445128 A1 PL445128 A1 PL 445128A1 PL 445128 A PL445128 A PL 445128A PL 44512823 A PL44512823 A PL 44512823A PL 445128 A1 PL445128 A1 PL 445128A1
Authority
PL
Poland
Prior art keywords
dione
pyrrole
hydroxyethyl
compounds
subject
Prior art date
Application number
PL445128A
Other languages
English (en)
Other versions
PL249318B1 (pl
Inventor
Janusz RACHOŃ
Mateusz Daśko
Karol Biernacki
Olga Ciupak
Sebastian DEMKOWICZ
Original Assignee
Politechnika Gdańska
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Politechnika Gdańska filed Critical Politechnika Gdańska
Priority to PL445128A priority Critical patent/PL249318B1/pl
Publication of PL445128A1 publication Critical patent/PL445128A1/pl
Publication of PL249318B1 publication Critical patent/PL249318B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
    • C07D207/448—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide
    • C07D207/452—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide with hydrocarbon radicals, substituted by hetero atoms, directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Przedmiotem wynalazku są związki chemiczne, będące akceptorami Michaela, charakteryzujące się strukturą chemiczną umożliwiającą ich wysoką reaktywność w reakcjach addycji Michaela, czyli addycji nukleofilowej do α,β-nienasyconych związków karbonylowych czy acylowych. Przedmiotem wynalazku jest pierwsze zastosowanie medyczne peptydowych pochodnych 1-(2-hydroksyetylo)-1H-pirolo-2,5-dionu. Przedmiotem wynalazku jest medyczne zastosowanie peptydowych pochodnych 1-(2-hydroksyetylo)-1H-pirolo-2,5-dionu jako leków, w tym zwłaszcza jako leków przeciwwirusowych o właściwościach inhibitora proteaz cysteinowych, w tym proteazy SARS CoV-2 Mpro oraz innych inhibitorów proteaz cysteinowych (zwanych również jako proteazy tiolowe). Wynalazek dotyczy również zastosowania tych związków do wykorzystania in vitro np. w diagnostyce jako inhibitorów proteazy cysteinowej, w tym proteazy SARS CoV-2 Mpro (ang. main protease- główna proteaza) oraz innych inhibitorów proteaz cysteinowych. W szczególności przedmiotowe związki peptydowe pochodne 1-(2-hydroksyetylo)-1H-pirolo-2,5-dionu znajdują zastosowanie medyczne jako leki w terapii przeciwwirusowej, a w szczególności w leczeniu infekcji wirusowych wywołanych koronawirusem SARS CoV-2, w tym COVID19 oraz innych koronawirusów odpowiedzialnych za ciężki ostry zespół oddechowy (SARS), zwłaszcza ssaków, w tym ludzi. Przedmiotem wynalazku jest ponadto sposób otrzymywania tych nowych związków na bazie peptydowych pochodnych 1-(2-hydroksyetylo)-1H-pirolo-2,5-dionu. Wynalazek znajduje praktyczne zastosowanie w medycynie i diagnostyce.
PL445128A 2023-06-06 2023-06-06 Peptydowe pochodne 1-(2-hydroksyetylo)-1H-pirolo-2,5-dionu, zastosowanie medyczne tych związków oraz sposób ich otrzymywania PL249318B1 (pl)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL445128A PL249318B1 (pl) 2023-06-06 2023-06-06 Peptydowe pochodne 1-(2-hydroksyetylo)-1H-pirolo-2,5-dionu, zastosowanie medyczne tych związków oraz sposób ich otrzymywania

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL445128A PL249318B1 (pl) 2023-06-06 2023-06-06 Peptydowe pochodne 1-(2-hydroksyetylo)-1H-pirolo-2,5-dionu, zastosowanie medyczne tych związków oraz sposób ich otrzymywania

Publications (2)

Publication Number Publication Date
PL445128A1 true PL445128A1 (pl) 2024-12-09
PL249318B1 PL249318B1 (pl) 2026-03-23

Family

ID=93799863

Family Applications (1)

Application Number Title Priority Date Filing Date
PL445128A PL249318B1 (pl) 2023-06-06 2023-06-06 Peptydowe pochodne 1-(2-hydroksyetylo)-1H-pirolo-2,5-dionu, zastosowanie medyczne tych związków oraz sposób ich otrzymywania

Country Status (1)

Country Link
PL (1) PL249318B1 (pl)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114432301A (zh) * 2020-11-03 2022-05-06 北京大学 一种共价抑制剂衍生物及其在治疗病毒感染方面的应用
WO2023283256A1 (en) * 2021-07-09 2023-01-12 Aligos Therapeutics, Inc. Anti-viral compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114432301A (zh) * 2020-11-03 2022-05-06 北京大学 一种共价抑制剂衍生物及其在治疗病毒感染方面的应用
WO2023283256A1 (en) * 2021-07-09 2023-01-12 Aligos Therapeutics, Inc. Anti-viral compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
IO ANTONOPOULOU, ELEFTHERIA SAPOUNTZAKI, ULRIKA ROVA, PAUL CHRISTAKOPOULOS: "Computational and Structural Biotechnology Journal, 2022, 20, 1306–1344", INHIBITION OF THE MAIN PROTEASE OF SARS-COV-2 (MPRO) BY REPURPOSING/DESIGNING DRUG-LIKE SUBSTANCES AND UTILIZING NATURE’S TOOLBOX OF BIOACTIVE COMPOUNDS *

Also Published As

Publication number Publication date
PL249318B1 (pl) 2026-03-23

Similar Documents

Publication Publication Date Title
Theoharides et al. Long‐COVID syndrome‐associated brain fog and chemofog: Luteolin to the rescue
MX2024014861A (es) Inhibidor de la prmt5 de tres anillos fusionados que contiene nitrogeno, y metodo de preparacion del mismo y uso farmaceutico del mismo
MX2025011950A (es) Inhibidores macrociclicos de ras
BR102021005055A2 (pt) detecção de anticorpos para sarsr-cov
BR112022007867A2 (pt) Degradadores de pequena molécula de helios e métodos de uso
BR112021023825A2 (pt) Inibidores heterobicíclicos de mat2a e métodos de uso para tratamento de câncer
CY1122366T1 (el) Θεραπεια της οξειας λεμφοβλαστικης λευχαιμιας
MX2025011947A (es) Inhibidores macrociclicos de ras
CY1118059T1 (el) Συνθεσεις αντιλοιμωδων βασει λιπιδιων για αγωγη πνευμονικων λοιμωξεων
BRPI0317717B8 (pt) composto, composição farmacêutica, e uso de um composto
BRPI0509172A (pt) pelo menos uma entidade quìmica, composição farmacêutica, métodos para tratar um paciente, para inibir pelo menos uma enzima que utiliza atp, e para tratar pelo menos uma doença, uso de pelo menos uma entidade quìmica, e, método para a fabricação de um medicamento
BR112015011497A2 (pt) composto, formulação farmacêutica, produto de combinação, e, método de tratamento de uma doença
ECSP088561A (es) Derivados de pirimidinil-aril-urea que son inhibidores de fgf
BR122020006906B8 (pt) compostos e composições farmacêuticas antivirais
BR0015056A (pt) Composto, uso de um composto, composição farmacêutica, método de tratamento de infecções por hiv e kit farmacêutico
CL2007001388A1 (es) Co-cristal de maleato de 2{etil[3-({4-[(5-{2-[(3-fluorfenil)amino]-2-oxoetil}-1h-pirazol-3-il)amino]quinazolin-7-il}oxi)propil]amino}fosfato dihidrogeno de etilo (azd1152), inhibidor de aurora quinasa; metodo de preparacion; composicion farmaceutica; y uso para el tratamiento de enfermedades hiperproliferativas como el cancer.
BR112022026186A2 (pt) Combinação de um inibidor de bromodomínio cbp/p300 e um inibidor de kras
BRPI0517564A (pt) métodos para modificar o destino de uma célula de adenoma e/ou adenocarcinoma, para induzir a formação de uma célula pós-mitótica a partir de um célula de adenoma e/ou adenocarcinoma e para, pelo menos em parte, diminuir um adenoma e/ou adenocarcinoma intestinal presente em um animal, uso de um inibidor do trajeto de notch, e, composição farmacêutica
MX2024004216A (es) Terapias combinadas de inhibidores de kras g12d con inhibidores de la familia pan erbb.
BRPI0415753A (pt) método para tratamento e prevenção da inflamação respiratória com um inibidor de ciclooxigenase-2 em associação com um inibidor de fosfodiesterase 4 e composições que os contêm
CY1124784T1 (el) Συν-κρυσταλλος απο του στοματος διαθεσιμου αναστολεα προλυλ υδροξυλασης hif
Slusarczyk et al. Retracted: Anti‐inflammatory properties of tianeptine on lipopolysaccharide‐induced changes in microglial cells involve toll‐like receptor‐related pathways
WO2022099187A3 (en) Sars-cov-2 antigen-binding proteins and uses thereof
MX2024009105A (es) Inhibidores de las cinasas cdk4/6.
MX2022014303A (es) Compuestos para el tratamiento del sars.